Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Six Months ended September 30, 2016
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets prescription and over-the-counter (OTC) finished pharmaceutical products, active pharmaceutical ingredients (APIs), and differentiated formulations.
Key Financial Metrics
All figures in Indian Rupees (Rs.) in millions, unless otherwise noted. Convenience translation to U.S. dollars provided where applicable (Rate: $1.00 = Rs. 66.58).
Income Statement Highlights (Six Months Ended Sept 30, 2016)
| Metric | 2016 (6 Months) | 2015 (6 Months) | Change |
|---|---|---|---|
| Revenues | Rs. 68,202 ($1,024M) | Rs. 77,467 | (12%) |
| Gross Profit | Rs. 38,275 ($575M) | Rs. 47,415 | (19%) |
| Gross Margin | 56.1% | 61.2% | -5.1 pts |
| Operating Profit | Rs. 4,574 ($69M) | Rs. 16,969 | (73%) |
| Net Profit | Rs. 4,213 ($63M) | Rs. 13,475 | (69%) |
| EPS (Basic) | Rs. 25.14 ($0.38) | Rs. 79.04 | (68%) |
Balance Sheet Highlights (As of Sept 30, 2016)
| Metric | Sept 30, 2016 | March 31, 2016 |
|---|---|---|
| Cash and Cash Equivalents | Rs. 2,443 ($37M) | Rs. 4,921 |
| Total Current Assets | Rs. 100,157 ($1,504M) | Rs. 119,688 |
| Total Assets | Rs. 220,415 ($3,311M) | Rs. 207,650 |
| Short-term Borrowings | Rs. 49,551 ($744M) | Rs. 22,718 |
| Long-term Borrowings | Rs. 10,677 ($160M) | Rs. 10,685 |
| Total Liabilities | Rs. 105,151 ($1,579M) | Rs. 79,314 |
| Total Equity | Rs. 115,264 ($1,731M) | Rs. 128,336 |
Cash Flow (Six Months Ended Sept 30, 2016)
- Operating Cash Flow: Rs. 7,763M inflow (vs. Rs. 19,992M in prior year).
- Investing Cash Flow: Rs. 17,292M outflow (vs. Rs. 6,250M outflow in prior year), driven by acquisitions.
- Financing Cash Flow: Rs. 7,224M inflow (vs. Rs. 12,580M outflow in prior year), driven by new borrowings offset by share buybacks and dividends.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenues decreased 12% (6-month) and 10% (quarterly) year-over-year. The decline was driven by:
- Global Generics: A 13% revenue drop due to price erosion, volume declines in North America (loss of market share in key molecules like Omeprazole and Azacitidine), and a voluntary reduction of supply to Venezuela due to economic instability.
- PSAI: A 9% revenue drop due to lower sales volumes and prices of APIs.
- Margin Compression: Gross margin declined from 61.2% to 56.1% (6-month) due to increased competitive intensity, lower realizations on key molecules, and higher overhead costs.
- Profitability Drop: Net profit fell 69% to Rs. 4,213M. Operating profit dropped 73% to Rs. 4,574M, impacted by higher SG&A expenses (up 9%) and R&D expenses (up 13%).
- Debt Increase: Short-term borrowings increased significantly to Rs. 49,551M (from Rs. 22,718M), primarily due to a Rs. 23,366M ($350M) loan taken by the Swiss subsidiary to fund the acquisition of eight ANDAs from Teva Pharmaceutical.
- Share Buyback: The company completed a buyback of 5.08 million equity shares for Rs. 15,694M during the period.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Strategic Acquisitions: DRL continues to invest in its pipeline, acquiring eight ANDAs from Teva ($350M), exclusive U.S. rights to a clinical-stage oral NCE from XenoPort ($47.5M), and OTC brands from Ducere Pharma ($17M).
- R&D Focus: Increased R&D spending reflects a strategy to expand efforts in complex formulations, differentiated formulations, and biosimilars.
- Market Dynamics: Management notes continued price erosion in North America and competitive pressure in key therapeutic areas.
Risks and Contingencies
- Regulatory Actions (FDA): The company received a warning letter in November 2015 regarding cGMP deviations at three Indian manufacturing facilities (Srikakulam, Miryalaguda, Duvvada). While production is not currently restricted, failure to resolve issues could lead to withholding of new product approvals or refusal of product admission into the U.S.
- Venezuela Operations: Ongoing economic crisis and currency devaluation have severely impacted revenues (down to Rs. 8M for 6 months vs. Rs. 3,105M prior year). The company has reduced supply as a risk mitigation strategy. Significant foreign exchange losses were recognized due to currency translation.
- Legal and Tax Litigation:
- NPPA (India): Litigation regarding price controls on Norfloxacin and cardiovascular/anti-diabetic formulations. A provision of Rs. 344M was recorded for potential liability on excess sales proceeds.
- U.S. Antitrust: Pending class action lawsuits regarding Nexium and Namenda settlements. The company believes liability is not probable but disputes remain.
- Child-Resistant Packaging: Investigations by the CPSC and DOJ regarding packaging compliance. No provision made as outcome is uncertain.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the revenue decline in North America and the extent of market share loss in key generic molecules.
- Debt Servicing: Assess the impact of the increased short-term debt (Rs. 49.5B) on future interest expenses and liquidity, particularly given the drop in operating cash flow.
- Regulatory Resolution: Monitor the status of the U.S. FDA warning letter response and the timeline for resolving cGMP deviations to ensure no future import bans.
- Venezuela Exposure: Confirm the current status of fund repatriation and the potential for further write-downs or foreign exchange losses given the volatile currency environment.
- Acquisition Integration: Track the commercialization timeline and revenue contribution of the newly acquired Teva ANDAs and XenoPort NCE.